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Abstract
Chlamydiae are obligate intracellular pathogens that are sensitive to pro-inflammatory cytokine interferon-c. IFN-c-inducible
murine p47 GTPases have been demonstrated to function in resistance to chlamydia infection in vivo and in vitro. Because
the human genome does not encode IFN-c-inducible homologues of these proteins, the significance of the p47 GTPase
findings to chlamydia pathogenesis in humans is unclear. Here we report a pair of IFN-c-inducible proteins, the human
guanylate binding proteins (hGBPs) 1 and 2 that potentiate the anti-chlamydial properties of IFN-c. hGBP1 and 2 localize to
the inclusion membrane, and their anti-chlamydial functions required the GTPase domain. Alone, hGBP1 or 2 have mild, but
statistically significant and reproducible negative effects on the growth of Chlamydia trachomatis, whilst having potent anti-
chlamydial activity in conjunction with treatment with a sub-inhibitory concentration of IFN-c. Thus, hGBPs appear to
potentiate the anti-chlamydial effects of IFN-c. Indeed, depletion of hGBP1 and 2 in cells treated with IFN-c led to an
increase in inclusion size, indicative of better growth. Interestingly, chlamydia species/strains harboring the full-length
version of the putative cytotoxin gene, which has been suggested to confer resistance to IFN-c was not affected by hGBP
overexpression. These findings identify the guanylate binding proteins as potentiators of IFN-c inhibition of C. trachomatis
growth, and may be the targets of the chlamydial cytotoxin.
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Introduction
Infections of the obligate intracellular pathogens chlamydiae
elicit an inflammatory Th1 response from the host resulting in
their eventual clearance, with interferon-c (IFN-c) playing a
prominent role in this process [1,2,3,4]. Seminal studies from
Byrne and colleagues have identified the IFN-c-induced gene
encoding for the catabolic enzyme indole 2,3-dideoxygenase
(IDO) as the primary anti-chlamydial effector of IFN-c [5]. IDO
functions by cleaving the essential amino acid tryptophan, for
which chlamydiae are auxotrophic, thus effectively starving the
chlamydiae and inducing a growth arrest [6,7,8,9,10].
IFN-c stimulation of cells in vivo and in vitro induces the
transcription of numerous genes that cooperate to eliminate
intracellular bacteria, and their roles in resolving bacterial
infections are just beginning to be understood at the molecular
level. There are other IFN-c-induced genes that have not been
characterized for bactericidal activity, and in addition to IDO may
be required for the full manifestation of the anti-chlamydial
function of this cytokine.
A prominent subset of these IFN-c-induced genes includes a
family of GTP-binding proteins, collectively termed large GTPases
to which the 65 kD guanylate binding proteins (p65 GBPs) belong
[11,12,13,14,15]. p65 GBPs represent well-conserved GTPases in
vertebrates, and are highly induced by IFN-c and less so by IFN-
a/b [13]. There are five known GBP genes present in the human
genome, and all are presumably induced by IFN-c, owing to the
presence of the interferon response element within their promoter
sequences [13,16]. hGBP1 and 2 have been demonstrated at the
protein level to be induced by IFN-c treatment. When maximally
induced, the guanylate binding proteins can represent up to 20%
of all the proteins induced by IFN-c [15]. Its IFN-c responsiveness
and high levels of expression are highly suggestive of a role in
effecting known IFN-c-mediated downstream processes, such as
immunity to viral pathogens or neovascularization during
inflammation [17,18,19,20,21,22]. In spite of its induction by
IFN-c, the role of hGBPs in the elimination of bacterial infections
has not been thoroughly explored [23].
The mode of action of hGBPs is unknown, although it is well
accepted that these proteins harbor a latent GTPase activity in its
monomeric form that is markedly increased during oligomeriza-
tion. Biochemical studies indicate that hGBP1 may hexamerize,
with this form being the most potent in hydrolyzing GTP to GDP
and GDP to GMP [15,24,25]. It has also been reported that stable
expression of hGBP1 in HeLa cells resulted in the significant
inhibition of vesicular stomatitis virus (VSV) and encephalomyo-
carditis virus (EMCV) replication, although its mode of action
appears to be different for both viruses [19]. Inhibition of the VSV
replication requires the N-terminal domain that contains a
canonical GTPase domain, while the C-terminal domain, which
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has a high degree of helical structures and an isoprenylation
(CAAX) domain, is necessary for limiting ECMV replication
possibly through direct interaction with the ECMV nucleocapsid
protein. Under IFN-c treatment, hGBP1 was observed to localize
to the Golgi apparatus [26]. However, this specific localization was
not observed in ectopically expressed hGBP1, indicating an IFN-c-
responsive co-factor that mediates the association of hGBP1 with
the Golgi apparatus. The role of hGBP’s association with the Golgi
apparatus in resistance to viral infections may not be important as
ectopic expression of hGBP1 alone was sufficient in arresting VSV
and ECMV replication.
In contrast to the limited knowledge of the antimicrobial effects
of hGBPs, the importance of murine p47 GTPases in clearing
chlamydia infection in mouse models has been reported and
confirmed [27,28,29]. Several p47 GTPases have been shown to
play a role in the restriction of C. trachomatis growth in murine cell
lines, with the first evidence reported by Nelson et al describing the
inhibitory effects on chlamydial growth by the p47 GTPase Iigp1
[29]. This study was followed by the identification of susceptibility
loci in the mouse genome that harbored genes for Igtp and Irgb10,
with the latter subsequently implicated directly on IFN-c-mediated
inhibition of chlamydial growth by associating with the inclusion
membrane [30,31]. In the same report, the murine homologue
(Irga6) of Iigp1 was found to be dispensable in the resistance to
chlamydia infection [28], a finding that is in conflict with that
reported by Al-Zeer et al [32]. It is possible that a functional
redundancy among these p47 GTPases exists and that the role of
Iigp1 is masked in vivo. The p47 GTPase orthologues present in the
human genome, IRGC and IRGM, are not inducible by IFN-c
[33,34]. IRGC is also presumed to be a pseudogene. Interestingly,
humans do not possess a p47 GTPase-based resistance. Thus, the
importance of the findings in murine models of infection is
unclear. The presence of hGBPs in the human genome, in
conjunction with its lack of genes encoding p47 GTPases suggests
that some function of the p47 GTPases in mice may be mediated
by hGBPs in humans. To address this hypothesis, the relationship
between hGBPs and chlamydial growth in cultured cells was
characterized. We report that hGBPs link IFN-c with its inhibition
of chlamydial growth by acting as a potentiator, rather than an
effector of the anti-chlamydial function of this cytokine.
Materials and Methods
Cell culture and reagents
HeLa 229 cells (CCL 1.2, ATCC) were grown as previously
described [35]. Infections with C. trachomatis LGV443 (serotype
L2), UW-3/CX (serotype D), and TW-5/OT (serotype B) (kindly
provided by Dr. Ted Hackstadt, LICP, NIAID) at multiplicities of
one were as previously described [35]. All experiments were
performed at least three independent times.
DNA constructs
TrueClones from OriGene encoding human GBP-1 (NM_002053)
and GBP2 (NM_004120) were cloned into expression vectors with N-
terminal c-Myc epitope tag (pCMV-Myc) or N-terminal hemaggluti-
nin tag (pCMV-HA), kindly provided by Dr. Leigh Knodler (LICP,
NIAID) for hGBP1 and hGBP2, respectively. Primers used were
hGBP1 FWD EcoRI (59 AAG AAT TCG GCA CGA GGG GAA
CA 39), hGBP1 REV Sal1 (59AAG TCG ACT CTT TAG CTT
ATG GTA CAT GCC 39), hGBP2 FWD SalI (59-AAG TCG ACC
ATGGCT CCA GAG ATC AAC -39), hGBP2 REV KpnI (59-AAG
GTACCTTAGAGTATGTTACATATTGGCTCCAATGA-
39), hGBP1 helical only FWDEcoR1 (59-AAGAATTCTCAACGG
GCC TCG TCT AGA-39), hGBP1 helical only REV Sal1 (59-AAG
TCG ACT TAG CTT ATG GTA CAT GCC TTT CG-39) were
used to amplify hGBP1. PCR products were cloned into TOPO TA
vectors (Invitrogen), and the insert removed by digestion with the
appropriate restriction enzymes and ligated into either the pCMV-Myc
or pCMV-HA vector. Integrity of the clones was verified by sequencing
and protein expression. A dominant-negative mutant for GBP-1
(D184N) [36] was generated using the pCMV-Myc GBP-1 construct,
the forward mutant primer 59 GAC TTT GTG TGG ACA CTG
AGA AAT TTC TCC CTG GAC 39 and reverse primer 59- TCT
CAG TGT CCA CAC AAA GTC TGG GAA GAA GCT CAC -39
and the GeneTailor Site-Directed Mutagenesis System (Invitrogen).
The mutant clones were verified by DNA sequence analysis.
Transfections and siRNA knockdown
Transfections were performed using the Fugene Transfection
Reagent (Roche) per the manufacturer’s suggestions, with slight
modifications. SiRNA transfections were performed using the
Ribojuice reagent, per the manufacturer’s instructions. Optimized
transfection conditions were as follows. Into 56104 HeLa cells
plated on coverslips and grown in 0.2 ml Opti-MEM a 50-ml
transfection mixture (30 nM siRNA consisting of three distinct
siRNAs complexed, 2 ml Ribojuice, 48 ml Opti-MEM) was
overlaid drop wise. siRNA used were from Ambion (human
GBP-1 - #16708A ID 10835, #16708A ID 10930 and #16708A
ID 11020; human GBP2 - Hs_GBP2_1 #S100425516,
Hs_GBP2_2 #S100425523 and Hs_GBP2_4 #S100425537).
To knockdown GBP-1 induced by human interferon-gamma
(IFN-c), cells were first incubated with siRNA transfection
complexes. After 4 hours of incubation, the siRNA was replaced
with cell culture medium containing 5 ng/ml IFN-c. After
24 hours, cells were infected with Chlamydia trachomatis as indicated
and the cytokine was kept in the medium during the whole cell
culture period. One day later cells on the coverslip were processed
for indirect immunofluorescence microscopy or immunoblots.
Western blots for actin of whole cell lysates of equal cell numbers
were used to monitor cytotoxicity of the siRNA treatment.
Real time PCR
Expression of human Guanylate Binding Protein (GBP)-1,
GBP2 and b-actin was assessed by isolating total RNA from 16106
HeLa cells using the TRIZOL reagent per the manufacturer’s
instructions, followed by reverse transcription ( 500 ng total RNA,
Superscript III Reverse Transcriptase system (Invitrogen cat
#18080-044), nonamer Random Primer 9 (New England Biolabs
cat #S1254S)) and quantitative real-time polymerase chain
reaction PCR. The QuantiTect primers for the gene GBP-1
(NM_002053; cat #QT01669885 or #QT00011641) with a
predicted amplicon length of 96 bp and custom designed primers
for GBP2 (FWD 59-GAC CAA ATG TTC CAG AGG AAA TTA
GGG GC-39, REV 59-AAT GTT CCC TGC TTG ACA TCT
TCT TCT AAA GG-39) were used. No cross amplification was
observed between the primer pairs. For the gene ACTB (b-actin),
cat #QT00095431 with a predicted amplicon length of 146 bp
was used. The amplification of a specific product was indepen-
dently verified further by analysis of the size of the end products of
the PCR on a 2% ethidium bromide agarose gel and comparison
with the corresponding predicted amplicon size. The quantitative
analysis of expression levels of specific products was calculated and
statistically evaluated using relative expression software tool from
Pfaffl, MW et al. (Pfaffl MW, Horgan GW, Dempfle L. Relative
expression software tool (REST) for group-wise comparison and
statistical analysis of relative expression results in real-time PCR.
Nucleic Acids Res. 2002 May 1;30(9):e36.). The expression of
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human b-actin was used as a reference gene to normalize the
target genes of interest.
Immunoblotting of whole cell lysates
Protein samples from whole cell lysates were analyzed by SDS-
PAGE and Western blot, as described previously [35]. Primary
antibodies used were anti-human GBP-1 (Oncogene, IM-1011),
anti-actin (Sigma A3853), anti-b-tubulin (Sigma T4026), anti-Myc
(Upstate clone 4A6) and anti-HA (Cell signaling clone 6E2).
Secondary HRP-conjugated goat anti-mouse or anti-rabbit
antibodies were from Pierce or Zymed.
Indirect immunofluorescence microscopy
Preparation of samples for confocal imaging was performed as
described previously [35]. Inclusions and transfected cells were
visualized using an Olympus Fluoview confocal microscope
(Olympus, Pittsburgh, PA) equipped with an argon and HeNe-G
laser. Images were processed using Adobe Photoshop CS.
Morphometric analysis and statistics
NIH Image J software (http://rsb.info.nih.gov/ij/) was used for
the morphometric analysis of chlamydial inclusions. Differences in
inclusion size under different growth conditions were analyzed by
the Wilcoxon Rank Sum test (mcardle.oncology.wisc.edu/mstat).
P-values of#0.05 were considered statistically significant. For the
statistical analysis of relative gene expression the Relative
Expression Software Tool was used. The pairwise allocation
function was employed with 2,000 iterations and p-values#0.05
were considered statistically significant.
Results
hGBPs induction by IFN-c correlated well with growth
inhibition of chlamydia
hGBPs are induced by treatment with IFN-c in other cell types, and
a similar IFN-c responsiveness was investigated in HeLa cells.
Expression levels of hGBP1 and 2 after treatment with different doses
of IFN-cwere examined by qRT-PCRat 24 h post-treatment. Figure 1
clearly demonstrated a mild, but noticeable induction of hGBP1 and 2
transcripts 24 h after treatment with 0.05 ng/ml dose of IFNc, a dose
that is inefficient in inhibiting the growth of various chlamydial strains
and species as evaluated by microscopy and inclusion forming unit
(IFU) assay. However, a robust increase was observed at a 10-fold
higher dose (0.5 ng/ml). The induction of hGBP1, for which
commercially available antibodies exist, could be readily observed in
situ by immunofluorescence staining, as well as in Western blot (data
not shown). At this IFN-c concentration, which resulted in at least a 13-
fold increase in transcript levels, clear inhibition of growth of C.
trachomatis serovars L2, B, and D occurred in HeLa cells treated for
24 h prior to infection. At the identical IFN-c concentration, IDO was
induced by nearly 25-fold at the transcript level. Therefore, HeLa cells
can induce hGBP1 and 2 in response to IFN-c treatment, and
increasing expression of hGBP1and 2, brought on by higher doses of
IFN-c correlated well with more efficient inhibition of growth of
different C. trachomatis serovars.
hGBP1 localizes to the chlamydial inclusion membrane
The hGBPs are isoprenylated at their C-terminus via the
CAAX domain, and the addition of this hydrophobic tag is
thought to mediate association with membranous structures
[21,26,36]. Therefore, localization of hGBP1 to the chlamydial
inclusion was investigated by confocal microscopy. HeLa cells pre-
transfected with the myc-tagged versions of the full-length or the
Figure 1. Induction of GBP under conditions that inhibit
chlamydial growth. A) Transcriptional response of hGBP1 (open
circle), hGBP2 (closed circle, solid line), and indole 2,3-dideoxygenase
(closed circle, dotted line) to different doses of IFN-c was monitored
after 18 h treatment. Data are expressed as fold difference relative to
mock-treated. B) Images of the inclusions of different C. trachomatis
serovars from a parallel dose-response experiments are shown. Scale
bars = 50 mm. C) IFU yields at 24 h p.i. (serovars L2, D) and 48 h p.i.
(serovar B) for the different IFN-c treatments.
doi:10.1371/journal.pone.0006499.g001
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C-terminal helical domain of hGBP1 were infected with C.
trachomatis serovar B EBs. At 24 h p.i., the samples were processed
for immunofluorescence microscopy. In Figure 2 chlamydia
inclusion displayed rim-like staining patterns for both the full-
length hGBP1 and the helical domain clones, indicating that the
helical domain is sufficient to localize hGBP1 to the membrane.
This is consistent with the CAAX isoprenylation motif localizing at
the end of the helical domain. Chlamydia inclusions in
untransfected cells on the same coverslip served as internal
controls for the specificity of the antibody against the myc-tag. A
similar rim-like staining pattern was observed for the HA-tagged
full-length hGBP2 (data not shown).
hGBP1 or 2 overexpression in HeLa cells delays C.
trachomatis growth
The induction of hGBP expression by IFN-c strongly implicates this
GTPase family in antimicrobial defense. To study the potential anti-
chlamydial activity of hGBP1 and 2 in the absence of any influence
from other IFN-c-induced genes, the genes encoding for hGBP1 and 2
were cloned under the control of the strong CMV promoter and
downstream of either the Myc or HA tags. HeLa cells were transfected
with myc-hGBP1 or HA-hGBP2, and at 24 h post-transfection, the
cells were infected with C. trachomatis serovars L2, B, or D EBs at 1
MOI. At 24 h post-infection, the cells were stained for either the Myc
or HA tag to identify cells expressing hGBP1 or hGBP2, respectively,
along with an anti-L2 EB polyclonal antibody, which was sufficiently
cross-reactive to recognize the other serovars used. Untransfected cells
among the transfected ones were used as internal negative controls.
Confocal images were obtained and each inclusion from either the
transfected or untransfected cells was measured morphometrically
using NIH ImageJ. Figure 3 shows a representative image of
transfected and untransfected cells harboring developing inclusions of
serovars L2, B, or D. Note the noticeably smaller size of inclusions
found within cells overexpressing Myc-hGBP1. The differences in
inclusion sizes were quantified by morphometric analysis and values
expressed in arbitrary units (AU) are shown in Figure 3. Inclusions of all
three C. trachomatis serovars growing in transfected cells were
significantly (p,0.05, Wilcoxon Rank Sum Test) smaller (L2 –
1.46160.89 AU, B – 0.36560.29 AU, D – 1.72561.63 AU) than
inclusion in the untransfected cells (L2-2.17761.26 AU, B –
2.25461.56 AU. D – 2.18261.47 AU). These data demonstrate that
overexpression of hGBP1 is sufficient to produce a noticeable and
statistically significant inhibition of chlamydial growth.
Because of the pronounced sensitivity of serovar B to hGBP1
overexpression, this serovar was used for subsequent studies. The
effects of overexpression of hGBP2 on the growth of Ctr serovar B
inclusions were evaluated. Indeed, a noticeable decrease in mean
size was consistently observed for serovar B inclusion found in cells
overexpressing hGBP2, indicating that like hGBP1, hGBP2 may
have anti-chlamydial function (Figure 4).
Inhibition of C. trachomatis growth by hGBP1 requires the
GTPase activity.
Because of the similar effects of hGBP1 and hGBP2 on Ctr serovar
B, functional analyses were focused on hGBP1. A structure/function
Figure 2. hGBP localizes to the inclusion membrane. HeLa cells were transfected with myc-GBP-1 expression construct (wt) and mutant
derivatives, D184N dominant negative mutant, and helical domain only and infected with CtrB at 24 h post-transfection. Coverslips were processed
24 h post infection using for indirect immunofluorescence assays and visualized by laser confocal microscopy. Whenever possible, a neighboring
untransfected cell harboring inclusions were shown.
doi:10.1371/journal.pone.0006499.g002
Anti-Chlamydial Role of hGBPs
PLoS ONE | www.plosone.org 4 August 2009 | Volume 4 | Issue 8 | e6499
study was performed to determine the requirement for the GTPase
domain.Mutant derivatives of hGBP included the deletion of the entire
GTPase domain, and aD184N point mutant that has been reported to
lack the GTPase activity [36]. At 24 h post-transfection, the cells were
infected with serovar B EBs, and the chlamydia was allowed to grow
for 24 h. Ctr serovar B was chosen for its sensitivity to hGBP1
overexpression. The samples were processed for immunofluorescence
imaging, and the area of each inclusion area was morphometrically
measured. The deletion mutant, and the subtler D184N point mutant
lost the ability to inhibit chlamydia growth (Figure 5).
hGBP1 and 2 knockdown partially relieved the chlamydia
growth inhibition by IFN-c
To further confirm the potentiating properties of overexpressed
hGBP1 in the context of IFN-c function, HeLa cells were
transfected with siRNAs for hGBP1 to reduce the level of the
protein in IFN-c-treated cells. At 48 h post-transfection, when the
level of hGBP1 protein was at its lowest relative to untransfected
cells during a 24-h treatment with IFN-c (5 ng/ml), the cells were
infected with C. trachomatis serovar B EBs. Ctr serovar B was chosen
for its relatively higher level of susceptibility to IFN-c treatment. It
should be noted that IFN-c was present 24 h prior to infection and
for an additional 24 h during infection. The cells were processed for
immunofluorescence confocal microscopy and morphometric
measurement of inclusions. Figure 6 shows representative confocal
images of inclusions in mock-transfected and siRNA-transfected
cells under identical magnification in the absence (A) or presence (B
and C) of IFN-c. In addition, the level of knockdown of hGBP1 at
the experimental conditions used (lane 11 of 12) is shown by the
accompanying Western blot. The size of the inclusions were
measured and statistically analyzed for any differences that may
have resulted from siRNA depletion of hGBP1. Measurement of at
Figure 3. Overexpression of hGBP1 inhibits chlamydial growth. Cells overexpressing Myc-hGBP1 harbor smaller inclusions from Ctr serovars
L2, B, and D. Samples were processed for immunostaining and confocal microscopy at 24 h post-infection. The size of the inclusion (red) in GBP-
expressing cells (green) was measured using NIH ImageJ and compared to untransfected internal controls at 24 h p.i. Morphometric analysis showed
a statistically significant difference (p,0.0001) in size of inclusions found in hGBP1-transfected (solid symbols) and untransfected cells (open symbols)
for all serovars tested. Mean values are indicated by black horizontal bars. Data were analyzed using the non-parametric Wilcoxon test (two-sided).
doi:10.1371/journal.pone.0006499.g003
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least 50 inclusions from each group yielded a statistically significant
difference (p,0.0003, Wilcoxon Rank Sum test) in inclusions sizes
among the mock-transfected (0.25560.106 AU) and hGBP1
siRNA-transfected (0.74260.233 AU) HeLa cells. Untreated cells
served as a control for the potency of the stock of IFN-c used. A
similar result was obtained for Ctr serovar L2 albeit with a more
moderate difference between mock and hGBP1-depleted groups
(data not shown). Better growth was obtained when the maximal
induction by IFN-c of hGBP1 was prevented by siRNA knockdown.
hGBP1 potentiated the anti-chlamydial activity of IFN-c
The anti-chlamydial activity associated with hGBP1 and 2
overexpression was relatively modest when compared to that of
IFN-c treatment. However, their robust induction by IFN-c
suggests a potential role in mediating some function of this
cytokine. Rather than being a direct effector of IFN-c with regards
to chlamydia growth inhibition, we hypothesized that hGBPs may
potentiate the effects of IFN-c. To test this hypothesis, HeLa cells
overexpressing myc-hGBP1 were treated with a sub-inhibitory
dose of IFN-c (0.05 ng/ml) at the time of infection (at 18 h post-
transfection) with Ctr serovar L2. Thus, cells were not pre-treated
with IFN-c. This strain was chosen for its relative resistance to
hGBP1 overexpression (Figure 3). Thus, any inhibition of Ctr L2
growth due to the concerted action of hGBP1 overexpression and
the sub-inhibitory concentration of IFN-c would be considered
significant. In untransfected cells, morphologically mature inclu-
sions could be seen in the presence of IFN-c at a dose (0.05 ng/ml)
that has been shown to be insufficient to negatively affect
chlamydial growth (Figure 1). Interestingly, noticeably smaller
inclusions could be observed in cells overexpressing hGBP1
(Figure 7 A-C), while no noticeable change in sizes of those in cell
expressing the D148N mutant were seen. The level of respon-
siveness of the cells was found to be unaltered by exposure to the
transfection reagent (Supplemental Figure S1). Furthermore, the
percentage of cells infected with chlamydia and transfected with
hGBP1-myc in IFN-c treated (10%) and mock-treated (42%)
populations were significantly different, suggesting that the
Figure 4. hGBP1 and hGBP2 have similar inhibitory effects on
C. trachomatis serovar B. HeLa cells overexpressing hGBP1 or hGBP2
were infected with Ctr serovar B at 24 h post-transfection, and analyzed
at 24 h post-infection. Mock-transfected cells from the same coverslips
were used as internal negative controls. Mean values are indicated by
black horizontal bars.
doi:10.1371/journal.pone.0006499.g004
Figure 5. Anti-chlamydial activities of hGBP1 require the
GTPase region. HeLa cells were transfected with constructs encoding
either wild type GBP-1 (wt), a dominant negative mutant (D148N). The
cells were infected with Ctr serovar B and processed for confocal
microscopy at 24 h p.i. Inclusions from the cells expressing the wild-
type form of hGBP1 were measured and statistically compared with the
cells expressing the D148N mutant (DN), the helical domain only (HD),
and mock-transfected using Mann-Whitney test. Mean inclusion sizes
are indicated by horizontal bars. P-value,0.005.
doi:10.1371/journal.pone.0006499.g005
Figure 6. Knock-down of hGBP1 partially restores growth of
chlamydia inclusions. Untreated (A) or IFN-c treated HeLa cells were
exposed to scrambled (B) or anti-hGBP1 (C) siRNA. At 24 h post-
transfection, the cells were infected with Chlamydia trachomatis serovar
B, and incubated for a further 24 h prior to processing of samples for
confocal microscopy. The total transfection and treatment times were
48 h. Scale bar = 20 mm. Inclusion areas of mock and hGBP1-depleted
samples were measured. Statistical significance (p,0.002) was deter-
mined using the Wilcoxon Rank Sum test (two-sided). The bottom panel
demonstrates the optimization of the 48-h transfection and co-
treatment protocol to achieve the maximum reduction in hGBP1 while
minimizing cytotoxicity.
doi:10.1371/journal.pone.0006499.g006
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combination of hGBP1 overexpression and the sub-inhibitory
concentration of IFN-c cooperated to kill and degrade internalized
EBs, rendering them undetectable by immunofluorescence. Taken
together, the data indicate that the sub-inhibitory concentration of
IFN-c could be sufficient in inhibiting chlamydial growth when
accompanied by hGBP1 overexpression.
A correlation between sensitivity to guanylate binding protein
overexpression and presence of the full-length cytotoxin gene.
A report by Nelson et al demonstrated that gamma-irradiated C.
muridarum EBs conferred IFN-c resistance to C. trachomatis serovar
D during growth in murine cells [29]. This apparent ‘‘acquired’’
resistance was attributed to the cytotoxin in C. muridarum EBs.
With hGBPs possessing anti-chlamydia activities, a survey of
different strains and species of chlamydia was conducted. Strains
and species chosen were C. trachomatis serovars L2, B, D, C. caviae
GPIC strain, and C. muridarum. Ctr L2 lacks the cytotoxin gene;
Ctr B and D encode a partial cytotoxin; C. caviae and C. muridarum
possess a full-length cytotoxin gene. Using a similar morphometric
analysis described above, an interesting correlation was observed
with regards to the presence of the cytotoxin (Figure 8). The
species with full-length cytotoxin genes were relatively resistant to
the hGBP overexpression. In contrast, the partial cytotoxin gene
was not sufficient to confer the same level of resistance, as shown
by retained sensitivity of Ctr B and D. Expectedly, the Ctr L2
serovar remained susceptible to hGBP overexpression. Also, rim-
like staining by hGBP1 was inconsistently observed for C.
muridarum inclusions (data not shown). Because of the irregular
morphology of the C. caviae inclusions, it was difficult to make any
conclusion as to the inclusion membrane localization of hGBP1.
Based on the results obtained for C. muridarum, the intact cytotoxin
may counteract the anti-chlamydial effects of hGBP overexpres-
sion by displacing them from the inclusion membrane. However,
the influence of other polymorphisms cannot be discounted at this
time.
Discussion
Interferon-c is required for the timely clearance of C. trachomatis
infection [37,38]. Its anti-chlamydial mechanism has been
attributed to the tryptophan catabolizing enzyme indole 2,3
dideoxygenase (IDO) [5,7,39]. In culture, the addition of excess
tryptophan in the growth media that was supplemented with IFN-
c at inhibitory concentrations resulted in the complete rescue of
chlamydial growth [5,7,39]. While IDO certainly is essential in
clearing chlamydia infection, it is likely that other anti-chlamydial
effectors of IFN-c exist to cooperatively eliminate chlamydia
infections in vivo.
We have identified a family of proteins that appears to
potentiate, rather than directly mediate the anti-chlamydial
function of IFN-c. They are the p65 guanylate binding proteins
(GBP), of which five isoforms have been identified in humans [34].
hGBPs constitute approximately 20% of the IFN-c induced
proteins [15,25], suggestive of its function in IFN-c-mediated
elimination of microbial/viral infections. hGBP1 has been
implicated in the resistance to VSV and ECMV infection, with
the anti-viral mechanism of GBP-1 requiring the GTPase function
[19,22]. Thus, one possible mechanism is the efficient hydrolysis of
GTP to GMP, via a GDP intermediate [24], and this GTPase
activity is greatly enhanced in vitro when GBPs hexamerize [40]. In
this report, we demonstrate the loss of anti-chlamydial activity of
hGBP1 when a mutation (D148N) that abrogated the GTPase
activity was introduced. Thus, growth inhibition of chlamydia by
hGBP1 and 2 could be due to their functions in signalling and/or
guanine nucleotide depletion.
Figure 7. hGBP1 potentiates the anti-chlamydial effects of IFN-c. Cell overexpressing myc-hGBP1 (A-C) or myc-hGBP D148N (D-F) were
treated with a sub-inhibitory concentration (0.05 ng/ml) of IFN-c at the time of infection with Ctr serovar L2 at MOI = 1 and processed for microscopy
at 24 h p.i. White arrows indicate inclusions within transfected cells. Scale bar = 50 mm.
doi:10.1371/journal.pone.0006499.g007
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An unexpected finding was the ability of hGBP1 to potentiate the
anti-chlamydial effects of IFN-c even at sub-inhibitory concentra-
tion of the cytokine. It should be noted that while the dose of IFN-c
used was insufficient to arrest chlamydial growth, a transcriptional
response to IFN-c treatment were still induced, as demonstrated by
the 4-fold increase in IDO induction in the presence of IFN-c
(0.05 ng/ml). At this dose, hGBP1 and 2 were also induced by 2 to 3
fold. Assuming cooperation between IDO, hGBP1 and 2, it would
appear that the respective levels of induction with 0.05 ng/ml IFN-
c were not sufficient to inhibit chlamydial growth. However, by
artificially increasing hGBP1 levels via ectopic overexpression, the
addition of the sub-inhibitory concentration of IFN-c became
sufficiently potent in negatively affecting the growth of Ctr serovar
B. This mode of action is reminiscent of a potentiator, rather than
an effector. Also, the relatively early induction of hGBPs in cultured
cells after exposure to IFN-c is consistent with this potentiating
function by making chlamydia more susceptible to the subsequent
assault of the many anti-bacterial effectors of IFN-c expressed.
The mode of action of hGBP1 and 2 are not known. However, we
did observe the localization of hGBP to the inclusion, and we speculate
that this localization mark the inclusions for interaction with
degradative compartments of the host cell. Interestingly, hGBP1 was
found to localize, albeit inconsistently to LC3-positive autophagosomes
of uninfected cells (Tietzel and Carabeo, unpublished observation).
The localization of hGBP1 to the chlamydial inclusion during
conditions of overexpression may render this parasitophorous vacuole
recognizable to the autophagy machinery, as has been shown by Al-
Zeer et al with the murine Irga6 [32]. Indeed, related murine p47
GTPases, which are not found in the human genome, are known to be
involved in autophagy and other mechanisms that promote the
interaction of the phagosome with degradative compartments within
the cell [41,42]. Irga6-mediated alteration of the chlamydial inclusion
may result in the non-fusogenicity of this pathogen-defined organelle
with sphingomyelin-containing vesicles originating from the trans-
Golgi. Indeed, Nelson et al observed the inhibition of SM traffic to the
inclusion [29].
In addition, localization of a subset of murine p47 GTPases
(Irgb10 and Irga6) to the inclusion correlated with susceptibility to
IFN-c with C. trachomatis inclusions, but not of the more resistant C.
muridarum positive for the GTPase proteins [32]. This observation
led to the speculation that localization of the p47 GTPases could
be determined by the cytotoxin content of the chlamydia.
While humans lack the homologous genes, the p65 GTPases to
which hGBPs belong may possess functions similar to the murine p47
GTPases. If hGBPs are indeed functioning within the context of the
anti-chlamydial function of IFN-c, then their depletion would be
expected to have noticeable effects on the efficiency of chlamydial
inhibition by this cytokine. Indeed, knockdown of hGBP1 and hGBP2
levels by siRNA in the presence of IFN-c visibly attenuated the anti-
chlamydial effects of this cytokine, further implicating an anti-
chlamydial role for these GTPases. The depletion experiments did
not lead to the complete restoration of inclusions to normal size, but
this result is not surprising given the number of potential anti-
chlamydial effectors induced by IFN-c that still remained. However,
the visible attenuation of growth inhibition upon their depletion
indicates a prominent role for these GTPases in resolving chlamydia
infection – an observation consistent with a potentiating mode of
function for hGBPs. Further supporting the potentiator model is the
demonstration of growth inhibition of inclusions growing in cells
overexpressing hGBP1 and concomitantly treated with sub-inhibitory
concentration (0.05 ng/ml) of IFN-c.
It should be noted that the proposed potentiator function of
hGBPs in IFN-c-mediated inhibition of chlamydial growth does
not necessarily contradict the previous findings regarding indole
2,3 dideoxygenase (IDO) as the major effector, as hGBPs may
sensitize chlamydia to tryptophan starvation. Possible mechanisms
may include prevention of nutrient acquisition through alterations
to inclusion properties. GTP depletion may also cooperate with
tryptophan depletion as guanosine synthesis is linked to trypto-
phan synthesis via the phosphoenolpyruvate carboxylase (PEC)
enzyme, which determines the levels of metabolic intermediates
within the tricarboxylic acid cycle [43,44]. Modulation of the
Figure 8. Correlation between sensitivity to hGBP1 overexpression and the presence of full-length cytotoxin. HeLa cells transfected
with hGBP1 were infected at 24 h post-transfection with C. trachomatis L2, B, or D strain, C. caviae serovar GPIC, and C. muridarum serovar MoPn. The
infection was terminated at 48 h post transfection and areas of inclusion in transfected (closed) and untransfected (open) cells were measured as
above. hGBP expression yielded statistically significant differences in inclusion size, except for hGBP1 expression in GPIC or MoPn-infected cells. *
indicate p,161025 in the two-sided Wilcoxon test.
doi:10.1371/journal.pone.0006499.g008
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levels of these intermediates has consequences on the biosynthesis
of downstream metabolites, such as guanosine and guanine
nucleotides, which are derived from a-ketoglutarate [45]. Both
scenarios could be alleviated by the addition of excess tryptophan
in the growth medium to bypass the potentiating effects of hGBP.
One interesting observation that was made was the relative
resistance to hGBP overexpression of chlamydia species that encode
the full-length cytotoxin. This piece of data implies that the cytotoxin,
which is homologous to clostridial toxins that target host GTP-binding
proteins, may neutralize hGBPs. Because the cellular target for the
toxin, or indeed its function have yet to be identified, this scenario
becomes an intriguing possibility. Nelson et al have already implied a
functional relationship between the cytotoxin and a member of the
murine p47 GTPases, although other polymorphisms within the
genome could account for the difference in susceptibility to IFN-g [29].
If indeed true, our data would lend further support to the GTPase-
inactivating function of the putative chlamydia toxin.
This report as a whole represents the first characterization of
hGBPs in the context of chlamydia infection. By identifying
hGBPs as potentiators of IFN-c function, we introduce a new
perspective to IFN-c-mediated suppression of chlamydial growth –
that the collection of IFN-c-induced genes with anti-chlamydial
functions could be classified as potentiators and effectors, with
hGBPs belonging to the former class, and IDO to the latter. Our
ongoing studies on the functions of hGBPs in chlamydia
pathogenesis should provide some insight into the mechanisms
of IFN-c-mediated clearance of bacterial infection in humans.
Supporting Information
Figure S1 Transfection reagents do not dampen the anti-
chlamydial function of IFN-c HeLa cells were exposed to mock,
Fugene, or Ribojuice transfection cocktail for 24 h. After removal
of the transfection reagents, the cells were infected with C.
trachomatis serovar L2 and immediately followed by treatment
with IFN-c (Mock - blue; 0.05 ng/ml - red; 0.5 ng/ml - green). At
24 h p.i., IFU yield was determined for each group and expressed
as values relative to the mock-treated group.
Found at: doi:10.1371/journal.pone.0006499.s001 (1.22 MB TIF)
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